Up-to-date List of Meloxicam Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Meloxicam Medical Research Studies

RankStatusStudy
1 Unknown  Study of a COX-2 Inhibitor for Prevention of Ovulation
Condition: Rupture; Graafian Follicle
Intervention: Drug: Meloxicam
Outcome Measures: Test the efficacy of Meloxicam in preventing ovulation as measured by ovarian follicular development and delay in rupture when is administered daily for 18 days, starting on the 5th day of the cycle.;   Occurrence of functioning corpus luteum subsequent to unruptured follicles;   Bleeding pattern during treatment with Meloxicam;   Incidence of adverse events;   Pharmacokinetics of Meloxicam;   Levels of estradiol;   Levels of progesterone;   Levels of LH
2 Recruiting A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
Conditions: Multiple Myeloma;   Non-Hodgkin's Lymphoma
Interventions: Drug: Meloxicam;   Drug: Filgrastim
Outcome Measures: Number of patients who mobilize and collect at least half of the total target CD34+ cell dose in the first apheresis;   Toxicity Profile of Meloxicam and Filgrastim;   Graft Composition of Peripheral Blood Stem Cell Collection;   Engraftment Kinetics of Meloxicam and Filgrastim
3 Not yet recruiting Meloxicam vs Placebo for Mobilization
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Multiple Myeloma;   Hematopoietic Stem Cells
Interventions: Drug: GCSF;   Drug: Meloxicam;   Drug: Placebo
Outcome Measures: numbers of circulating CD34+ cells on the first day of apheresis;   number of apheresis sessions required to collect ³ 5 x 10^6 CD34+ cells/kgCD34+ cells/kg;   time to neutrophil and platelet engraftment after AHSCT;   identify the toxicities associated with Meloxicam when used with GCSF for stem cell mobilization.;   number of red cell and platelet transfusions prior to engraftment;   Proportion of patients failing stem cell mobilization.
4 Unknown  Study Comparing A New Drug Containing The Combination Meloxicam And Cyclobenzaprine In The Treatment Of Acute Lumbago
Condition: Acute Lumbago
Interventions: Drug: Meloxicam/cyclobenzaprine hydrochloride;   Drug: Meloxicam - Movatec®;   Drug: cyclobenzaprine - Miosan®
Outcome Measures: Pain Reduction;   Frequency of rescue medication use
5 Recruiting TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial
Condition: Tuberculosis
Intervention: Drug: Meloxicam 7.5mg daily for 8 weeks
Outcome Measures: Incidence of TB IRIS;   Proportion discontinuing Meloxicam due to adverse event;   The proportion of patients in each arm with the following indicators of TB-IRIS severity/quality of life (QOL) (degree of pain or discomfort >III;   The proportion of patients with local or disseminated suppuration/abscess of any site, unscheduled clinic visits, hospitalizations, missed more than a day at work, etc
6 Recruiting Discontinuing NSAIDs
Condition: Knee Osteoarthritis
Interventions: Drug: Meloxicam 15 mg po QD;   Behavioral: Cognitive Behavioral Therapy
Outcome Measures: The primary endpoint will be between-group differences in the WOMAC pain score (Likert Scale version) measured at 4 weeks.;   Area under the curve (AUC) of the WOMAC pain scale score over the observation period: AUC will be measured in order to capture the variability in pain that is characteristic of knee OA .;   Intermittent vs. Constant Pain;   Lower extremity disability;   Global impression of change;   Adherence to study medication and use of co-therapies
7 Recruiting Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)
Condition: Pilon Fracture
Interventions: Drug: NSAID;   Drug: Gabapentinoids;   Drug: placebo
Outcome Measures: Opioid Utilization;   Persistent Pain;   Surgery for non-union;   Post Surgical Pain Intensity;   Pre Surgical Pain Intensity;   Length of Index Hospitalization;   Adverse Effects and Complications;   Functional Outcome;   Generic Health Status;   Depressive Symptoms;   Post Traumatic Stress (PTSD);   Medical Costs;   Fracture Severity;   Fracture Classification
8 Unknown  Arthroplasty Versus Fusion in Anterior Cervical Surgery: Prospective Study of the Impact on the Adjacent Level
Conditions: Clinical Radiculopathy;   Myelopathy Due to a Cervical Disk Disease
Interventions: Device: cervical disc prosthesis with a mobile insert named Mobi-C;   Procedure: arthrodesis - cervical disk surgery
Outcome Measures: show significant difference of degeneration of disc above and below the operated stage between the two groups;   show difference of neurological pain between the two groups;   show difference of duration of hospitalization and consumption of medication
9 Recruiting The Effect on Knee Joint Loads of Analgesic Use Compared With Exercise in Patients With Knee Osteoarthritis - An RCT
Condition: Osteoarthritis, Knee
Interventions: Drug: Instruction on analgesic use for pain relief (acetaminophen and NSAIDs);   Other: Neuromuscular exercise
Outcome Measures: Change from baseline in 1st peak RMS (root mean square) Knee Index.;   Change from baseline in 1st peak Knee adduction moment;   Change from baseline in the KOOS (Knee injury and Osteoarthritis Outcome Score) questionnaire;   Change from baseline in Maximum number of one-leg rises from stool test;   Change from baseline in Maximum number of knee-bendings in 30s test;   Change from baseline in One-leg hop for distance test
10 Not yet recruiting Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164)
Condition: Low Back Pain
Interventions: Drug: MK-0663B;   Drug: DOLOCAM PLUS®;   Drug: Acetaminophen 500 mg
Outcome Measures: Number of Participants Experiencing an Adverse Event (AE);   Number of Participants Discontinuing Study Treatment Due to an AE;   Mean Change From Baseline in the Participant Low Back Pain Questionnaire Score;   Mean Change From Baseline in the Participant Roland Morris Disability Questionnaire;   Number of Participants With ≥30% Improvement From Baseline in the Roland Morris Disability;   Mean Change From Baseline in the Participant Global Assessment of Response to Therapy.;   Mean Change From Baseline in the Investigator Global Assessment of Response to Therapy;   Average Amount of Rescue Medication Required by Participant During Study Treatment;   Proportion of Participants Using Rescue Medication During Study Treatment

These studies may lead to new treatments and are adding insight into Meloxicam etiology and treatment.

A major focus of Meloxicam research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Meloxicam

© Copyright 2019.

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly. PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.

Privacy | Terms | Contact us
Share
Popular Pages